Robert Paul, PA
Physician Assistant · Chula Vista, CANPI 1972811412
Payments from drug & device makers
Across 479 payments — averaging $32.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Nevro Corp.$2K
- Saluda Medical Americas, Inc.$2K
- Biohaven Pharmaceutical Holding Company Ltd.$1K
- Relievant Medsystems, Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$970
- plus $5K from 30 others
What the payments were for
- Consulting fees$8005%
- Travel & lodging$3,20721%
- Food & beverage$11,27874%
- Education$560%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 34 | $2,827 |
| Nevro Corp. | 64 | $1,830 |
| Saluda Medical Americas, Inc. | 7 | $1,522 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $1,495 |
| Relievant Medsystems, Inc. | 9 | $1,308 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 67 | $970 |
| Forte Bio-pharma LLC | 61 | $942 |
| Collegium Pharmaceutical, Inc. | 57 | $854 |
| Nalu Medical, Inc. | 28 | $400 |
| Abbott | 34 | $382 |
| AbbVie(2 entities) | 17 | $359 |
| Axonics, Inc. | 3 | $289 |
| Curonix LLC | 12 | $286 |
| Vertos Medical, Inc. | 6 | $226 |
| Painteq LLC | 5 | $211 |
| Scilex Pharmaceuticals Inc. | 14 | $197 |
| Merz Pharmaceuticals, LLC | 3 | $172 |
| Lilly USA, LLC | 7 | $139 |
| Biohaven Pharmaceuticals, Inc. | 7 | $129 |
| Azurity Pharmaceuticals, Inc. | 5 | $95 |
| Pfizer | 4 | $78 |
| Hikma Pharmaceuticals USA | 4 | $74 |
| Arbor Pharmaceuticals, Inc. | 5 | $74 |
| Si-bone, Inc. | 2 | $73 |
| Foundation Fusion Solutions, LLC | 1 | $65 |
| Amgen | 3 | $59 |
| Kowa Pharmaceuticals America, Inc. | 3 | $53 |
| Novo Nordisk | 2 | $48 |
| Spinal Simplicity, LLC | 2 | $42 |
| GRT US Holding, Inc. | 1 | $23 |
| Globus Medical | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Bioventus LLC | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$2,668
- WaveWriter Alpha Prime 16$1,807
- Evoke SCS$1,467
- NURTEC ODT$1,378
- Omnia$406
- Axonics$283
- Senza$138
- XEOMIN$134
- mild Device Kit$119
- SUPERION$112
- PAINTEQ$104
How this compares
$15,341 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 687 | $215,728 |
| BelbucaBuprenorphine Hcl | 107 | $77,305 |
| Buprenorphine | 287 | $67,047 |
| Xtampza ErOxycodone Myristate | 77 | $38,614 |
| RelistorMethylnaltrexone Bromide | 11 | $31,760 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 922 | $26,577 |
| MovantikNaloxegol Oxalate | 35 | $24,317 |
| ZtlidoLidocaine | 37 | $24,284 |
| HorizantGabapentin Enacarbil | 20 | $15,160 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 52 | $9,868 |
| Hysingla ErHydrocodone Bitartrate | 16 | $6,450 |
| Methocarbamol | 49 | $6,016 |
| ButransBuprenorphine | 15 | $5,938 |
| Gabapentin | 287 | $5,722 |
| Lidocaine | 33 | $4,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $854 | $115,919184 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate | $74 | $77,818381 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $970 | $31,76011 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $197 | $24,28437 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $74 | $15,16020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Chula Vista
- James LynchChula Vista$32K
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.